dailypolitical.com
Positivewww.dailypolitical.com ·
nurix therapeutics inc nasdaqnrix given average recommendation of moderate buy by brokerages
CRISISLEX_C03_WELLBEING_HEALTHMANMADE_DISASTER_IMPLIEDWB_2299_PIPELINESWB_539_OIL_AND_GAS_POLICY_STRATEGY_AND_INSTITUTIONS
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedNurix Therapeutics (NRIX) is a biotech company. Analyst ratings and price targets indicate moderate buy consensus, but the company reported a quarterly loss and revenue miss. Insider sales suggest potential lack of confidence. No direct commercial mechanism or supply chain impact is evident; the news is primarily equity analyst sentiment and insider trading disclosure. Impact is single-company-specific.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Average rating 'Moderate Buy' from 15 analysts; 13 buy, 1 sell, 1 strong buy.
- Average 12-month price target $30.46; stock at $16.60.
- Market cap $1.72 billion; 52-week range $8.19-$22.50.
- Quarterly loss $0.79 per share on revenue $6.25 million, missing estimates.
- Insider sales: Gwenn Hansen sold 3,214 shares; CFO Houte Hans Van sold 14,055 shares.